<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">35115598</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Feb</Month><Day>03</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Investigation of the prognostic predictive value of serum lipid profiles in amyotrophic lateral sclerosis: roles of sex and hypermetabolism.</ArticleTitle><Pagination><StartPage>1826</StartPage><MedlinePgn>1826</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1826</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-022-05714-w</ELocationID><Abstract><AbstractText>The prognostic predictive value of lipid profiling in amyotrophic lateral sclerosis (ALS) remains unclear. Here, we aimed to clarify the value of the levels of serum lipids, including high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), and triglycerides (TG), for predicting the prognosis in ALS. This was a single-center retrospective study of 78 patients with ALS. The serum lipid profiles at the first hospital visit after symptom onset were analyzed to determine the correlations of lipids with survival and physical parameters, including nutritional, respiratory, and metabolic conditions. The cutoff level for high HDL was defined as the third quartile, while that of low LDL and TG, as the first quartile. Hypermetabolism was defined as the ratio of resting energy expenditure to lean soft tissue mass&#x2009;&#x2265;&#x2009;38&#xa0;kcal/kg. High HDL was an independent factor for poor prognosis in all patients (hazards ratio [HR]: 9.87, p&#x2009;&lt;&#x2009;0.001) in the Cox proportional hazard model, including %vital capacity and the monthly decline rate in body mass index and the Revised Amyotrophic Lateral Functional Rating Scale score from symptom onset to diagnosis. Low LDL was a factor for poor prognosis (HR: 6.59, p&#x2009;=&#x2009;0.017) only in women. Moreover, subgroup analyses with log-rank tests revealed that the prognostic predictive value of high HDL was evident only in the presence of hypermetabolism (p&#x2009;=&#x2009;0.005). High HDL predicts poor prognosis in all patients, whereas low LDL, only in women. Hypermetabolism and high HDL synergistically augment the negative effect on prognosis.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Ryutaro</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Shiga University of Medical Science, Tsukinowa, Seta, Shiga, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurihara</LastName><ForeName>Mika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Clinical Nutrition, Shiga University of Medical Science, Tsukinowa, Seta, Shiga, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ogawa</LastName><ForeName>Nobuhiro</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Shiga University of Medical Science, Tsukinowa, Seta, Shiga, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kitamura</LastName><ForeName>Akihiro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Shiga University of Medical Science, Tsukinowa, Seta, Shiga, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamakawa</LastName><ForeName>Isamu</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurology, Shiga University of Medical Science, Tsukinowa, Seta, Shiga, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bamba</LastName><ForeName>Shigeki</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Clinical Nutrition, Shiga University of Medical Science, Tsukinowa, Seta, Shiga, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanada</LastName><ForeName>Mitsuru</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Shiga University of Medical Science, Tsukinowa, Seta, Shiga, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sasaki</LastName><ForeName>Masaya</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Clinical Nutrition, Shiga University of Medical Science, Tsukinowa, Seta, Shiga, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Urushitani</LastName><ForeName>Makoto</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Shiga University of Medical Science, Tsukinowa, Seta, Shiga, Japan. uru@belle.shiga-med.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008076">Cholesterol, HDL</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008078">Cholesterol, LDL</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014280">Triglycerides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015992" MajorTopicYN="N">Body Mass Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008076" MajorTopicYN="N">Cholesterol, HDL</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008078" MajorTopicYN="N">Cholesterol, LDL</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050356" MajorTopicYN="N">Lipid Metabolism</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014280" MajorTopicYN="N">Triglycerides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>4</Day><Hour>5</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35115598</ArticleId><ArticleId IdType="pmc">PMC8814149</ArticleId><ArticleId IdType="doi">10.1038/s41598-022-05714-w</ArticleId><ArticleId IdType="pii">10.1038/s41598-022-05714-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chi&#xf2; A, Logroscino G, Hardiman O, et al. Prognostic factors in ALS: A critical review. Amyotroph Lateral Scler. 2009;10:310&#x2013;323. doi: 10.3109/17482960802566824.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960802566824</ArticleId><ArticleId IdType="pmc">PMC3515205</ArticleId><ArticleId IdType="pubmed">19922118</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph AC, Dorst J, Dreyhaupt J, et al. Effect of high-caloric nutrition on survival in amyotrophic lateral sclerosis. Ann Neurol. 2019;2020(87):206&#x2013;216. doi: 10.1002/ana.25661[publishedOnlineFirst:19December.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25661[publishedOnlineFirst:19December</ArticleId><ArticleId IdType="pubmed">31849093</ArticleId></ArticleIdList></Reference><Reference><Citation>Khamankar N, Coan G, Weaver B, et al. Associative increases in amyotrophic lateral sclerosis Survival duration with non-invasive ventilation initiation and usage protocols. Front Neurol. 2018;9:578. doi: 10.3389/fneur.2018.00578.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.00578</ArticleId><ArticleId IdType="pmc">PMC6052254</ArticleId><ArticleId IdType="pubmed">30050497</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouteloup C, Desport JC, Clavelou P, et al. Hypermetabolism in ALS patients: an early and persistent phenomenon. J Neurol. 2009;2009(256):1236&#x2013;1242. doi: 10.1007/s00415-009-5100-z[publishedOnlineFirst:24March.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-009-5100-z[publishedOnlineFirst:24March</ArticleId><ArticleId IdType="pubmed">19306035</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyn FJ, Ioannides ZA, van Eijk RPA, et al. Hypermetabolism in ALS is associated with greater functional decline and shorter survival. J Neurol Neurosurg Psychiatry. 2018;2018(89):1016&#x2013;1023. doi: 10.1136/jnnp-2017-317887[publishedOnlineFirst:1May.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-317887[publishedOnlineFirst:1May</ArticleId><ArticleId IdType="pmc">PMC6166607</ArticleId><ArticleId IdType="pubmed">29706605</ArticleId></ArticleIdList></Reference><Reference><Citation>He J, Fu J, Zhao W, et al. Hypermetabolism associated with worse prognosis of amyotrophic lateral sclerosis. J Neurol. 2021 doi: 10.1007/s00415-021-10716-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-021-10716-1</ArticleId><ArticleId IdType="pubmed">34274994</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyn FJ, Li R, Kirk SE, et al. Altered skeletal muscle glucose-fatty acid flux in amyotrophic lateral sclerosis. Brain Commun. 2020;2:fcaa154. doi: 10.1093/braincomms/fcaa154(2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcaa154(2020)</ArticleId><ArticleId IdType="pmc">PMC7677608</ArticleId><ArticleId IdType="pubmed">33241210</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura R, Kurihara M, Ogawa N, et al. Prognostic prediction by hypermetabolism varies depending on the nutritional status in early amyotrophic lateral sclerosis. Sci Rep. 2021;11:17943. doi: 10.1038/s41598-021-97196-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-97196-5</ArticleId><ArticleId IdType="pmc">PMC8429558</ArticleId><ArticleId IdType="pubmed">34504168</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin B, Desport JC, Kajeu P, et al. Alteration of nutritional status at diagnosis is a prognostic factor for survival of amyotrophic lateral sclerosis patients. J Neurol Neurosurg Psychiatry. 2010;2011(82):628&#x2013;634. doi: 10.1136/jnnp.2010.211474[publishedOnlineFirst:19November.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2010.211474[publishedOnlineFirst:19November</ArticleId><ArticleId IdType="pubmed">21097551</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorst J, K&#xfc;hnlein P, Hendrich C, et al. Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis. J Neurol. 2010;2011(258):613&#x2013;617. doi: 10.1007/s00415-010-5805-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-010-5805-z</ArticleId><ArticleId IdType="pubmed">21128082</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang R, Guo X, Chen X, et al. The serum lipid profiles of amyotrophic lateral sclerosis patients: a study from south-west China and a meta-analysis. Amyotroph Lateral Scler Frontotemporal Degener. 2015;2015(16):359&#x2013;365. doi: 10.3109/21678421.2015.1047454.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1047454</ArticleId><ArticleId IdType="pubmed">26121273</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrioli J, Rosi E, Fini N, et al. Changes in routine laboratory tests and survival in amyotrophic lateral sclerosis. Neurol Sci. 2017;2017(38):2177&#x2013;2182. doi: 10.1007/s10072-017-3138-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-017-3138-8</ArticleId><ArticleId IdType="pubmed">28980128</ArticleId></ArticleIdList></Reference><Reference><Citation>Rafiq MK, Lee E, Bradburn M, et al. Effect of lipid profile on prognosis in the patients with amyotrophic lateral sclerosis: insights from the olesoxime clinical trial. Amyotroph Lateral Scler Frontotemporal Degener. 2015;2015(16):478&#x2013;484. doi: 10.3109/21678421.2015.1062517[publishedOnlineFirst:10July.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1062517[publishedOnlineFirst:10July</ArticleId><ArticleId IdType="pubmed">26161993</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda K, Hirayama T, Takazawa T, et al. Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: a cross-sectional study. Intern Med. 2012;2012(51):1501&#x2013;1508. doi: 10.2169/internalmedicine.51.7465[publishedOnlineFirst:15June.</Citation><ArticleIdList><ArticleId IdType="doi">10.2169/internalmedicine.51.7465[publishedOnlineFirst:15June</ArticleId><ArticleId IdType="pubmed">22728481</ArticleId></ArticleIdList></Reference><Reference><Citation>Wuolikainen A, Acimovic J, L&#xf6;vgren-Sandblom A, et al. Cholesterol, oxysterol, triglyceride, and coenzyme Q homeostasis in ALS. Evidence against the hypothesis that elevated 27-hydroxycholesterol is a pathogenic factor. PLoS ONE. 2014;9:e113619. doi: 10.1371/journal.pone.0113619.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0113619</ArticleId><ArticleId IdType="pmc">PMC4240598</ArticleId><ArticleId IdType="pubmed">25415378</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Calvo A, Ilardi A, et al. Lower serum lipid levels are related to respiratory impairment in patients with ALS. Neurology. 2009;73:1681&#x2013;1685. doi: 10.1212/WNL.0b013e3181c1df1e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181c1df1e</ArticleId><ArticleId IdType="pubmed">19917991</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Calvo A, Bovio G, et al. Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study. JAMA Neurol. 2014;71:1134&#x2013;1142. doi: 10.1001/jamaneurol.2014.1129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.1129</ArticleId><ArticleId IdType="pubmed">25048026</ArticleId></ArticleIdList></Reference><Reference><Citation>Barros ANAB, Dourado MET, Pedrosa LFC, et al. Association of copper status with lipid profile and functional status in patients with amyotrophic lateral sclerosis. J Nutr Metab. 2018;2018:5678698. doi: 10.1155/2018/5678698.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/5678698</ArticleId><ArticleId IdType="pmc">PMC6079445</ArticleId><ArticleId IdType="pubmed">30116640</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Luo X, Chen X, et al. Lipid profile in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis. Front Neurol. 2020;11:567753. doi: 10.3389/fneur.2020.567753.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.567753</ArticleId><ArticleId IdType="pmc">PMC7593382</ArticleId><ArticleId IdType="pubmed">33178110</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingre C, Chen L, Zhan Y, et al. Lipids, apolipoproteins, and prognosis of amyotrophic lateral sclerosis. Neurology. 2020;2020(94):e1835&#x2013;e1844. doi: 10.1212/WNL.0000000000009322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000009322</ArticleId><ArticleId IdType="pmc">PMC7274849</ArticleId><ArticleId IdType="pubmed">32221024</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III) J Neurol Sci. 1999;169:13&#x2013;21. doi: 10.1016/s0022-510x(99)00210-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0022-510x(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordestgaard BG, Langsted A, Mora S, et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J. 2016;2016(37):1944&#x2013;1958. doi: 10.1093/eurheartj/ehw152[publishedOnlineFirst:26April.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehw152[publishedOnlineFirst:26April</ArticleId><ArticleId IdType="pmc">PMC4929379</ArticleId><ArticleId IdType="pubmed">27122601</ArticleId></ArticleIdList></Reference><Reference><Citation>Takaoka A, Sasaki M, Kurihara M, et al. Comparison of energy metabolism and nutritional status of hospitalized patients with Crohn's disease and those with ulcerative colitis. J Clin Biochem Nutr. 2015;2015(56):208&#x2013;214. doi: 10.3164/jcbn.14-95[publishedOnlineFirst:14April.</Citation><ArticleIdList><ArticleId IdType="doi">10.3164/jcbn.14-95[publishedOnlineFirst:14April</ArticleId><ArticleId IdType="pmc">PMC4454083</ArticleId><ArticleId IdType="pubmed">26060351</ArticleId></ArticleIdList></Reference><Reference><Citation>Desport JC, Preux PM, Magy L, et al. Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis. Am J Clin Nutr. 2001;74:328&#x2013;334. doi: 10.1093/ajcn/74.3.328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcn/74.3.328</ArticleId><ArticleId IdType="pubmed">11522556</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris JA, Benedict FG. A biometric study of human basal metabolism. Proc Natl Acad Sci USA. 1918;4:370&#x2013;373. doi: 10.1073/pnas.4.12.370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.4.12.370</ArticleId><ArticleId IdType="pmc">PMC1091498</ArticleId><ArticleId IdType="pubmed">16576330</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyake R, Tanaka S, Ohkawara K, et al. Validity of predictive equations for basal metabolic rate in Japanese adults. J Nutr Sci Vitaminol (Tokyo) 2011;57:224&#x2013;232. doi: 10.3177/jnsv.57.224.</Citation><ArticleIdList><ArticleId IdType="doi">10.3177/jnsv.57.224</ArticleId><ArticleId IdType="pubmed">21908945</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2012;2013(48):452&#x2013;458. doi: 10.1038/bmt.2012.244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bmt.2012.244</ArticleId><ArticleId IdType="pmc">PMC3590441</ArticleId><ArticleId IdType="pubmed">23208313</ArticleId></ArticleIdList></Reference><Reference><Citation>Dedic SI, Stevic Z, Dedic V, et al. Is hyperlipidemia correlated with longer survival in patients with amyotrophic lateral sclerosis? Neurol Res. 2012;2012(34):576&#x2013;580. doi: 10.1179/1743132812Y.0000000049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/1743132812Y.0000000049</ArticleId><ArticleId IdType="pubmed">22732100</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson S, Gustafsson N, Warner M, et al. Inactivation of liver X receptor beta leads to adult-onset motor neuron degeneration in male mice. Proc Natl Acad Sci USA. 2005;2005(102):3857&#x2013;3862. doi: 10.1073/pnas.0500634102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0500634102</ArticleId><ArticleId IdType="pmc">PMC553330</ArticleId><ArticleId IdType="pubmed">15738425</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi CI, Lee YD, Gwag BJ, et al. Effects of estrogen on lifespan and motor functions in female hSOD1 G93A transgenic mice. J Neurol Sci. 2007;2008(268):40&#x2013;47. doi: 10.1016/j.jns.2007.10.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2007.10.024</ArticleId><ArticleId IdType="pubmed">18054961</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang S, Tabet F, Cochran BJ, et al. Apolipoprotein A-I enhances insulin-dependent and insulin-independent glucose uptake by skeletal muscle. Sci Rep. 2019;9:1350. doi: 10.1038/s41598-018-38014-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-38014-3</ArticleId><ArticleId IdType="pmc">PMC6362284</ArticleId><ArticleId IdType="pubmed">30718702</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehti M, Donelan E, Abplanalp W, et al. High-density lipoprotein maintains skeletal muscle function by modulating cellular respiration in mice. Circulation. 2013;2013(128):2364&#x2013;2371. doi: 10.1161/CIRCULATIONAHA.113.001551.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.113.001551</ArticleId><ArticleId IdType="pmc">PMC3957345</ArticleId><ArticleId IdType="pubmed">24170386</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Peng D. Regulation of adipocyte autophagy&#x2013;the potential anti-obesity mechanism of high density lipoprotein and apolipoproteinA-I. Lipids Health Dis. 2012;11:131. doi: 10.1186/1476-511X-11-131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1476-511X-11-131</ArticleId><ArticleId IdType="pmc">PMC3478219</ArticleId><ArticleId IdType="pubmed">23039759</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzo E, Lorenzini I, Barrameda D, et al. Glycolysis upregulation is neuroprotective as a compensatory mechanism in ALS. Elife. 2019 doi: 10.7554/eLife.45114.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.45114</ArticleId><ArticleId IdType="pmc">PMC6557627</ArticleId><ArticleId IdType="pubmed">31180318</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferri A, Coccurello R. What is "hyper" in the ALS hypermetabolism? Mediators Inflamm. 2017;2017:7821672. doi: 10.1155/2017/7821672.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/7821672</ArticleId><ArticleId IdType="pmc">PMC5610793</ArticleId><ArticleId IdType="pubmed">29081604</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruckert E, Baccara-Dinet M, McCoy F, et al. High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients. Curr Med Res Opin. 2005;21:1927&#x2013;1934. doi: 10.1185/030079905X74871.</Citation><ArticleIdList><ArticleId IdType="doi">10.1185/030079905X74871</ArticleId><ArticleId IdType="pubmed">16368042</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>